April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Different FTY720 (fingolimod) Treatment Regimens Can Suppress Autoimmune Uveoretinitis
Author Affiliations & Notes
  • David A. Copland
    School of Clinical Sciences, University of Bristol, Bristol, United Kingdom
  • Volker Brinkmann
    Autoimmunity, Transplantation & Inflammation, ATI, Novartis Institutes for BioMedical Research, Basel, Switzerland
  • Karen Anderson
    Ophthalmology, Novartis Institutes For Biomedical Research, Inc, Cambridge, Massachusetts
  • Jian Liu
    School of Clinical Sciences, University of Bristol, Bristol, United Kingdom
  • Lindsay B. Nicholson
    School of Clinical Sciences, University of Bristol, Bristol, United Kingdom
  • Andrew D. Dick
    School of Clinical Sciences, University of Bristol, Bristol, United Kingdom
  • Footnotes
    Commercial Relationships  David A. Copland, None; Volker Brinkmann, Novartis (E); Karen Anderson, Novartis (E); Jian Liu, None; Lindsay B. Nicholson, None; Andrew D. Dick, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4301. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      David A. Copland, Volker Brinkmann, Karen Anderson, Jian Liu, Lindsay B. Nicholson, Andrew D. Dick; Different FTY720 (fingolimod) Treatment Regimens Can Suppress Autoimmune Uveoretinitis. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4301.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To determine the efficacy of a non-steroid approach to suppressing active intraocular inflammation and inducing long term disease remission. Previous experimental autoimmune uveoretinitis (EAU) studies demonstrate that a short-term high dose treatment with Fingolimod (FTY720) a sphingosine-1-phosphatase analogue prevents T-cell migration to inflammatory sites and rapidly reduces ocular infiltrate. This suggests the clinical potential to serve as a rescue therapy for active ocular inflammatory conditions. EAU serves as a preclinical model of human uveitis, and permits assessment of immunotherapeutic efficacy.

Methods: : EAU was induced in B10.RIII mice by immunization with hRBP-3161-180, and disease severity determined by clinical assessment and flow cytometric analysis of retinal infiltrate. Groups of mice were treated following onset of clinical disease with a single oral dose of FTY720 or control vehicle at different concentrations (10, 1 and 0.1 mg/kg). Retinal infiltrate was examined and enumerated by flow cytometric methods, 24 hours after drug administration. In further experiments following disease onset, mice received a repetitive (X5 doses) low dose regimen of FTY720 or control (0.3mg/kg daily), with assessment of infiltrate at 24 hours after the final dose. Long-term efficacy of repeated FTY720 treatment was assessed on day 25, using histological methods to determine disease severity and vascular integrity.

Results: : Retinal infiltrate 24 hours following single dose treatment demonstrate 78% reduction of CD4+ cells in mice receiving the highest dose of FTY720 compared to control animals, and this reduction is dose dependent and significant even at the lowest dose. Mice treated from disease onset with a repetitive low dose regimen of 0.3 mg/kg FTY720 demonstrate 75% reduction in retinal infiltrate, and reduced clinical disease scores. Furthermore, the degree of macrophage and neutrophil infiltrate was also reduced by 60% and 50% respectively as compared to controls.

Conclusions: : These results demonstrate the potential clinical benefit that FTY720 may bring to the treatment of ocular immune-mediated inflammation, as a non-steroid based rescue and maintenance therapeutic.

Keywords: uveitis-clinical/animal model • autoimmune disease • immunomodulation/immunoregulation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.